These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9248605

  • 1. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP.
    Am J Health Syst Pharm; 1997 Jul 15; 54(14):1614-8. PubMed ID: 9248605
    [Abstract] [Full Text] [Related]

  • 2. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
    Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP.
    Am J Health Syst Pharm; 2003 Nov 15; 60(22):2321-7. PubMed ID: 14652981
    [Abstract] [Full Text] [Related]

  • 3. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL, Foster RH, Benfield P.
    Pharmacoeconomics; 1998 Jan 15; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [Abstract] [Full Text] [Related]

  • 4. An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.
    Smyth ET, Barr JG, O'Neill CA, Hogg GM.
    Pharmacoeconomics; 1995 Dec 15; 8(6):541-50. PubMed ID: 10160082
    [Abstract] [Full Text] [Related]

  • 5. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM, Sanz Chinesta S, Jiménez Cruz JF, Flores Corral N, Unda Urzaiz M, Leiva Galvis O, González Romojaro V, Hernández Fernández C, Lledó García E, Rioja Sanz LA, Gonzalvo Ibarra A, Camacho González JE, Ruíz Alvárez-Cienfuegos F, Resel Estévez L, Corral Saleta J, Burgos Rodríguez R, Del Rosal Samaniego JM.
    Actas Urol Esp; 1997 Dec 15; 21(7):668-74. PubMed ID: 9412209
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F, Anderson AN, Ebrahim O.
    S Afr Med J; 1998 Mar 15; 88(3):251-5. PubMed ID: 9608289
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic exchange of cefotaxime for ceftriaxone: evaluation, implementation, and subsequent cost savings at a 300-bed community hospital.
    Rawlings RD.
    Diagn Microbiol Infect Dis; 1995 Mar 15; 22(1-2):235-7. PubMed ID: 7587046
    [Abstract] [Full Text] [Related]

  • 8. Randomized study of cefotaxime versus ceftriaxone for uncomplicated gonorrhea.
    Mogabgab WJ, Lutz FB.
    South Med J; 1994 Apr 15; 87(4):461-4. PubMed ID: 8153771
    [Abstract] [Full Text] [Related]

  • 9. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK, Glenn DJ.
    Diagn Microbiol Infect Dis; 1995 Apr 15; 22(1-2):231-3. PubMed ID: 7587045
    [Abstract] [Full Text] [Related]

  • 10. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost.
    Hotchkies L, Grima DT, Hedayati S.
    Clin Ther; 1996 Apr 15; 18(4):716-25; discussion 702. PubMed ID: 8879899
    [Abstract] [Full Text] [Related]

  • 11. A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery.
    Anderson G, Boldiston C, Woods S, O'Brien P.
    Arch Surg; 1996 Jul 15; 131(7):744-8. PubMed ID: 8678775
    [Abstract] [Full Text] [Related]

  • 12. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.
    Simmons BP, Gelfand MS, Grogan J, Craft B.
    Diagn Microbiol Infect Dis; 1995 Jul 15; 22(1-2):155-7. PubMed ID: 7587031
    [Abstract] [Full Text] [Related]

  • 13. Evaluating the cost-effectiveness of treatment with third-generation cephalosporins.
    Gladen HE.
    Diagn Microbiol Infect Dis; 1992 Jan 15; 15(1):99-105. PubMed ID: 1730191
    [Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F, Del-Angel-García G, Ramírez Cuenca A, Malváez-Valdes M, Vega Yáñez A, Amato D.
    Rev Invest Clin; 2000 Jan 15; 52(4):418-26. PubMed ID: 11061104
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis.
    Friedland LR, Kulick RM, Biro FM, Patterson A.
    Ann Emerg Med; 1996 Mar 15; 27(3):299-304. PubMed ID: 8599487
    [Abstract] [Full Text] [Related]

  • 16. Reduction of hospital costs and administration of prophylactic antibiotherapy in gynecological surgery.
    Hell-Türler KT.
    Isr J Med Sci; 1992 Oct 15; 28(10):751. PubMed ID: 1399513
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian tertiary care institution.
    Tin LY, Pitre M, Conly JM.
    Diagn Microbiol Infect Dis; 1995 Oct 15; 22(1-2):135-40. PubMed ID: 7587028
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.